Show simple item record

dc.contributor.authorSabzichi, M
dc.contributor.authorHamishehkar, H
dc.contributor.authorRamezani, F
dc.contributor.authorSharifi, S
dc.contributor.authorTabasinezhad, M
dc.contributor.authorPirouzpanah, M
dc.contributor.authorGhanbari, P
dc.contributor.authorSamadi, N
dc.date.accessioned2018-08-26T06:04:41Z
dc.date.available2018-08-26T06:04:41Z
dc.date.issued2014
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/41542
dc.description.abstractNuclear factor erythroid 2-related factor 2 (Nrf2) has been recognized as a transcription factor that controls mechanisms of cellular defense response by regulation of three classes of genes, including endogenous antioxidants, phase II detoxifying enzymes and transporters. Previous studies have revealed roles of Nrf2 in resistance to chemotherapeutic agents and high level expression of Nrf2 has been found in many types of cancer. At physiological concentrations, luteolin as a flavonoid compound can inhibit Nrf2 and sensitize cancer cells to chemotherapeutic agents. We reported luteolin loaded in phytosomes as an advanced nanoparticle carrier sensitized MDA-MB 231 cells to doxorubicin. In this study, we prepared nano phytosomes of luteolin to enhance the bioavailability of luteolin and improve passive targeting in breast cancer cells. Our results showed that co- treatment of cells with nano particles containing luteolin and doxorubicin resulted in the highest percentage cell death in MDA-MB 231 cells (p<0.05). Furthermore, luteolin-loaded nanoparticles reduced Nrf2 gene expression at the mRNA level in cells to a greater extent than luteolin alone (p<0.05). Similarly, expression of downstream genes for Nrf2 including Ho1 and MDR1 were reduced significantly (p<0.05). Inhibition of Nrf-2 expression caused a marked increase in cancer cell death (p<0.05). Taken together, these results suggest that phytosome technology can improve the efficacy of chemotherapy by overcoming resistance and enhancing permeability of cancer cells to chemical agents and may thus be considered as a potential delivery system to improve therapeutic protocols for cancer patients.
dc.language.isoEnglish
dc.relation.ispartofAsian Pacific journal of cancer prevention : APJCP
dc.subjectAntineoplastic Agents
dc.subjectBiological Availability
dc.subjectBreast Neoplasms
dc.subjectCarcinoma
dc.subjectCell Death
dc.subjectCell Line, Tumor
dc.subjectDoxorubicin
dc.subjectDrug Carriers
dc.subjectFemale
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectLuteolin
dc.subjectNF-E2-Related Factor 2
dc.subjectNanoparticles
dc.subjectPermeability
dc.subjectSignal Transduction
dc.titleLuteolin-loaded phytosomes sensitize human breast carcinoma MDA-MB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling.
dc.typearticle
dc.citation.volume15
dc.citation.issue13
dc.citation.spage5311
dc.citation.epage6
dc.citation.indexPubmed


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record